Small Molecule Innovative Drugs
Empowering small molecule innovative drug R&D with a deep understanding of chemical scenarios, building an efficient and compliant integrated data and AI agent-driven solution.
Challenge: The vast expanse of literature and patent data makes it time-consuming and labor-intensive to manually extract structure-activity relationships (SAR), hindering systematic exploration of potential targets and hit compounds.
Challenge: Paper records are error-prone, difficult to trace, and inefficient for collaboration. Synthetic routes and experimental conditions often rely on personal experience, making them hard to preserve and reuse.
Challenge: Compound and sample information is scattered across multiple versions of Excel, leading to chaotic numbering, delayed updates of activity data, and ineffective SAR analysis.
Challenge: Chemical reagents cannot be searched by structure, leading to significant waste from duplicate purchases. Cumbersome procurement processes and opaque logistics information hinder experimental progress.
Challenge: Project schedules are often delayed, and cost accounting lags behind. Project documentation is separated from experimental data, making knowledge retention difficult.InProject Research
We understand that choosing an R&D platform is not just about selecting software tools; it is about choosing a continuously evolving, living product. More importantly, it is about selecting a strategic partner who understands your business and can support your growth for the next 10 or 20 years. To this end, we have built a unique combination of value.
We provide end-to-end platform solutions that ensure the seamless flow integration of data across every stage—from target discovery, lead optimization, and activity testing to DMPK, CMC, toxicology studies, CTD reporting, IND filing, and clinical bioanalysis. This approach allows you to completely eliminate the data silos and redundant work typically associated with managing multiple disparate systems.
We deeply integrate electronic lab notebooks, AI large models, and human scientific research knowledge graphs throughout core stages such as molecular design, experiment optimization, and report generation. Through continuous iteration and evolution, we aim to transform data into insights, elevate information into decisions, and truly unlock the intelligent potential of data.
From the very beginning, the platform is designed with embedded compliance requirements from major global regulatory agencies such as the FDA and NMPA (e.g., 21 CFR Part11、ALOCA+). This makes compliance and audit trails a natural part of the workflow, significantly reducing regulatory submission risks.
We provide professional services led by domain experts. Our implementation team not only understands the technology but also has years of in-depth experience in the field of small molecule innovative drug R&D. By leveraging best practices from over 700 clients, we help you quickly get started and plan the optimal implementation path, ensuring the platform perfectly aligns with your R&D workflows.
We maintain a dedicated Customer Success team to provide you with ongoing support following the system's launch. This team will proactively assist you in optimizing your workflows, assess your core requirements, continuously iterate on new features, and offer forward-looking recommendations to ensure you consistently maximize the return on your investment.
Every feature and scenario design is rooted in our profound understanding of this field—specifically its specialized know-how, R&D challenges, working habits, and regulatory landscape. This translates into less need for customization, a superior fit for your operations, and a solution that allows experts in small-molecule innovative drugs to directly address your specific pain points.
